Depomed (DEPO) Tops Q3 EPS by 3c, Revenue Comes in Light
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall St set to fall at open as yields and oil rebound; Fed minutes in focus
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Musk rules out TSMC role in Terafab operations; Intel gains
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- HubSpot to cut 7% of workforce in restructuring plan
- Caribou Biosciences to halt CAR-T programs, explore sale
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Stryker names Spencer Stiles as CEO, Lobo moves to chair
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
Depomed Announces Third Quarter 2017 Financial Results
November 7, 2017 4:07 PM EST- Third Quarter Net Sales of $95 Million-
- Slán Medicinal Holdings Transaction Creates New Specialty Unit and Diversifies Business -
- Updates Full-Year Guidance -
- Conference Call Scheduled for Today at 4:30 PM EST; Dial In Information Below -
NEWARK, Calif., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq: DEPO) today reported financial results for the quarter ended September 30, 2017 and provided an update to the business.
During the third quarter, we made... More



